JP7562557B2 - ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用する非ホジキンリンパ腫の処置方法 - Google Patents

２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用する非ホジキンリンパ腫の処置方法 Download PDF

Info

Publication number
JP7562557B2
JP7562557B2 JP2021559978A JP2021559978A JP7562557B2 JP 7562557 B2 JP7562557 B2 JP 7562557B2 JP 2021559978 A JP2021559978 A JP 2021559978A JP 2021559978 A JP2021559978 A JP 2021559978A JP 7562557 B2 JP7562557 B2 JP 7562557B2
Authority
JP
Japan
Prior art keywords
compound
days
day
pharmaceutical composition
cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021559978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527398A (ja
JP2022527398A5 (https=
Inventor
ソラジャ カランシオ アントン，マリア
ジェイ バックホルツ，トニア
ロペス－ヒロナ，アントニア
クリシュナ ナルラ，ラマ
プーダーナッド，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2022527398A publication Critical patent/JP2022527398A/ja
Publication of JP2022527398A5 publication Critical patent/JP2022527398A5/ja
Application granted granted Critical
Publication of JP7562557B2 publication Critical patent/JP7562557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021559978A 2019-04-12 2020-04-09 ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用する非ホジキンリンパ腫の処置方法 Active JP7562557B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833432P 2019-04-12 2019-04-12
US62/833,432 2019-04-12
PCT/US2020/027358 WO2020210418A1 (en) 2019-04-12 2020-04-09 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Publications (3)

Publication Number Publication Date
JP2022527398A JP2022527398A (ja) 2022-06-01
JP2022527398A5 JP2022527398A5 (https=) 2023-04-17
JP7562557B2 true JP7562557B2 (ja) 2024-10-07

Family

ID=70465546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559978A Active JP7562557B2 (ja) 2019-04-12 2020-04-09 ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用する非ホジキンリンパ腫の処置方法

Country Status (26)

Country Link
US (3) US11390617B2 (https=)
EP (1) EP3952880B1 (https=)
JP (1) JP7562557B2 (https=)
KR (1) KR102944213B1 (https=)
CN (1) CN114144182B (https=)
AR (1) AR119715A1 (https=)
AU (1) AU2020270917B2 (https=)
BR (1) BR112021020372A2 (https=)
CA (1) CA3132538A1 (https=)
CL (1) CL2021002651A1 (https=)
DK (1) DK3952880T3 (https=)
ES (1) ES3061998T3 (https=)
FI (1) FI3952880T3 (https=)
HR (1) HRP20251668T1 (https=)
IL (1) IL287145A (https=)
LT (1) LT3952880T (https=)
MA (1) MA55608A (https=)
MX (1) MX2021012507A (https=)
PT (1) PT3952880T (https=)
RS (1) RS67593B1 (https=)
SG (1) SG11202111232RA (https=)
SI (1) SI3952880T1 (https=)
SM (1) SMT202600013T1 (https=)
TW (1) TWI853014B (https=)
WO (1) WO2020210418A1 (https=)
ZA (1) ZA202107668B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CN115919870B (zh) 2019-10-21 2024-07-02 新基公司 化合物在制备用于治疗慢性淋巴细胞白血病的药物中的用途
PL4048278T3 (pl) 2019-10-21 2024-03-18 Celgene Corporation Sposoby leczenia złośliwych nowotworów hematologicznych z zastosowaniem 2-(2,6-dioksopiperydyn-3-ylo)-4-((2-fluoro-4-((3- morfolinoazetydyn-1-ylo)metylo)benzylo)amino)izoindolino-1,3-dionu
WO2021080931A1 (en) 2019-10-21 2021-04-29 Celgene Corporation Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneand salts thereof, and compositions comprising the same and their use
IL292305A (en) * 2019-10-21 2022-06-01 Celgene Corp Methods for the treatment of hematological cancer and the use of associated biomarkers for 2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isodonyl 1,3-discussion
US11583536B2 (en) * 2019-10-21 2023-02-21 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
AU2020370039B2 (en) * 2019-10-21 2026-02-19 Celgene Corporation Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same
MX2023011370A (es) * 2021-03-29 2023-11-24 Juno Therapeutics Inc Combinacion de una terapia con celulas t con receptores de antigenos quimericos (car) y un compuesto inmunomodulador para el tratamiento de linfoma.
AR125390A1 (es) * 2021-04-21 2023-07-12 Celgene Corp Métodos de tratamiento del linfoma no hodgkin con 2-(2,6-dioxopiperidin-3-il)-4-((2-lfuoro-4-((3-morfolinoazetidin-1-il) metil)benzil)amino)isoindoline-1,3-diona
IL305490A (en) * 2021-04-21 2023-10-01 Celgene Corp Methods of treating b-cell lymphoma using combination therapy
AU2022300184A1 (en) 2021-06-21 2023-11-16 Celgene Corporation Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7458324B2 (ja) 2018-04-23 2024-03-29 セルジーン コーポレイション 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374609T1 (de) 2000-11-30 2007-10-15 Childrens Medical Center Synthese von 4-aminothalidomid enantiomeren
CL2007002670A1 (es) * 2006-09-15 2008-05-16 Celgene Corp Soc Organizada Ba Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.
BRPI1007855B1 (pt) 2009-05-19 2020-03-10 Celgene Corporation Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
AU2013299627C1 (en) * 2012-08-09 2018-05-31 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
EP2914112A4 (en) 2012-11-05 2016-06-15 Celgene Corp TREATMENT OF CANCER WITH POMALIDOMIDE ON A PERSON WITH AFFECTED KIDNEY FUNCTION
BR112015025252A2 (pt) 2013-04-02 2017-07-18 Celgene Corp métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
EP4467143B1 (en) * 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7458324B2 (ja) 2018-04-23 2024-03-29 セルジーン コーポレイション 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用

Also Published As

Publication number Publication date
HRP20251668T1 (hr) 2026-02-27
AU2020270917A1 (en) 2021-11-04
US20200325129A1 (en) 2020-10-15
AR119715A1 (es) 2022-01-05
US11390617B2 (en) 2022-07-19
CN114144182A (zh) 2022-03-04
LT3952880T (lt) 2026-01-26
EP3952880A1 (en) 2022-02-16
ZA202107668B (en) 2025-01-29
RS67593B1 (sr) 2026-01-30
MX2021012507A (es) 2022-01-24
FI3952880T3 (fi) 2026-02-05
KR20210151895A (ko) 2021-12-14
JP2022527398A (ja) 2022-06-01
SMT202600013T1 (it) 2026-03-09
DK3952880T3 (da) 2026-01-26
US20220324855A1 (en) 2022-10-13
TW202103705A (zh) 2021-02-01
CL2021002651A1 (es) 2022-04-29
PT3952880T (pt) 2026-02-17
US20240400548A1 (en) 2024-12-05
MA55608A (fr) 2022-02-16
KR102944213B1 (ko) 2026-03-26
ES3061998T3 (en) 2026-04-08
WO2020210418A1 (en) 2020-10-15
TWI853014B (zh) 2024-08-21
AU2020270917B2 (en) 2025-08-28
EP3952880B1 (en) 2025-12-10
BR112021020372A2 (pt) 2021-12-07
IL287145A (en) 2021-12-01
US12103923B2 (en) 2024-10-01
SI3952880T1 (sl) 2026-02-27
CA3132538A1 (en) 2020-10-15
CN114144182B (zh) 2024-05-24
SG11202111232RA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
JP7562557B2 (ja) ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用する非ホジキンリンパ腫の処置方法
JP7581345B2 (ja) ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを用いて慢性リンパ性白血病を治療する方法
CN107073122A (zh) 恶性肿瘤的联合治疗
EA047955B1 (ru) Способы лечения неходжкинской лимфомы с использованием 2-(2,6-диоксопиперидин-3-ил)-4-((2-фтор-4-((3-морфолиноазетидин-1-ил)метил)бензил)амино)изоиндолин-1,3-диона
AU2020369497C1 (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
WO2022226011A1 (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
US20240207281A1 (en) Methods of treating b-cell lymphoma using combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240925

R150 Certificate of patent or registration of utility model

Ref document number: 7562557

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150